Most Recent
Full Court shoots down Boehringer opposition to Merck Sharp & Dohme’s parasite patent
Intellectual Property 2022-05-19 3:38 pm By Cat Fredenburgh

The Full Federal Court has rejected German drug maker Boehringer Ingelheim’s appeal of ruling that shot down its opposition to Merck Sharp & Dohme’s patent […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

High Court asked to decide if AI can be inventor on patent
Intellectual Property 2022-05-18 1:23 pm By Cat Fredenburgh

The High Court has been asked to wade into the debate over whether artificial intelligence can be named as an inventor on patent applications, after […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

Judge erred in finding AI can be patent inventor, Full Court says
Intellectual Property 2022-04-14 3:39 pm By Miklos Bolza

The Full Court has overturned a landmark judgment which found artificial intelligence can be named as an inventor on patent applications, in a decision which […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

ACCC says agreement to settle Revlimid patent suit could violate cartel laws
Intellectual Property 2022-03-23 2:53 pm By Cat Fredenburgh

The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

Full Court deals drug companies a blow on patent term extensions
Intellectual Property 2022-03-18 10:27 pm By Miklos Bolza

The Full Court has upheld two judgments that shortened patent term extensions granted to Merck Sharpe & Dohme and Ono Pharmaceuticals, finding the extension regime […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

High Court finds Sandoz infringed Lundbeck’s Lexapro patent
High Court 2022-03-09 4:40 pm By Miklos Bolza

The High Court has found that Novartis unit Sandoz infringed Danish drug company Lundbeck’s patent for its blockbuster antidepressant Lexapro, but has overturned a ruling […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

Jellycat’s Bashful Bunny plush toy ‘hardly a revolutionary concept’, court told
Intellectual Property 2022-03-01 6:18 pm By Bianca Hrovat

A toy designer that has been sued for allegedly copying the design of toy maker Jellycat’s beloved ‘Bashful Bunny’ has pushed back at a request […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

Celgene drops patent suit against Dr Reddy’s over Revlimid generic
Intellectual Property 2022-02-25 11:15 am By Cat Fredenburgh

Bristol-Myers Squibb unit Celgene has dropped a lawsuit accusing Indian generics company Dr Reddy’s Laboraties of threatening to infringe its patent for Revlimid with the […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

Full Court parks opposition to patent for detecting parking overstays
Appeals 2021-12-09 12:01 pm By Miklos Bolza

Tech company Vehicle Management Systems has come up short in its third attempt to block competitor SARB Management Group’s patent application for a magnetic parking […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

Dr Reddy’s must warn Celgene of plans to sell generic blockbuster cancer drug
Intellectual Property 2021-12-07 2:55 pm By Cindy Cameronne

Indian generics giant Dr Reddy’s Laboratories must give Bristol-Myers Squib unit Celgene Corporation three months’ notice before deciding to sell generic versions of blockbuster cancer […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.